NIPER Raebareli signs MoU with Roche Pharma India to strengthen Research (See 'Corp Brief') Sonowal interacts with Crew; calls Seafarers 'unsung heroes of Global Trade' (See 'Corp Brief') ITDC, Ministry of Tribal Affairs inaugurate Capacity Building Program for Tribal Homestay Owners (See 'Corp Brief') Food Processing Industry Must Align with Nutrition Security Goals (See 'Corp Brief') Trade Marks - Quasi-judicial authorities exercising statutory powers under the Trade Marks Act must pass a reasoned & speaking order after considering evidences & submissions placed; failure to do so amounts to abdication of these functions: HC (See 'Legal Desk') Raksha Mantri to inaugurate Conclave on 'Advanced Manufacturing Technologies' (See 'Corp Brief') Govt strengthens Institutional Credit Framework for Agriculture and Allied Sectors (See 'Corp Brief') Centre encouraging cash crops in place of tobacco: Chouhan (See 'Corp Brief') Over 1 Lakh Startups have at least One-Woman Director: Govt (See 'Corp Brief') PMLA - Allegations of mala fide cannot be accepted without specific evidence against ED officials; search authorization & consequent actions are distinct from scheduled offences u/s 3 of PMLA: HC (See 'Legal Desk') MoSPI has initiated measures to strengthen accountability in data collection (See 'Corp Brief') Govt expands Youth Skill Development through NSS, Skill India Mission and NEP Initiatives (See 'Corp Brief') Govt boosts Renewable Energy Awareness Nationwide (See 'Corp Brief') Misc - Doctrine of lis pendens u/s 52 of TOPA is not applicable to transfer of property that occurs before institution of suit concerning that property, especially when transferor is not party to subsequent suit: HC (See 'Legal Desk') CCI organises 11th Edition of National Conference on Economics of Competition Law (See 'Corp Brief') India submits Report on Implementation of Nagoya Protocol for Biodiversity (See 'Corp Brief') MSME Champion Scheme progressing well towards achieving its objectives (See 'Corp Brief') A&C - Law provides award creditor with additional option to file for execution directly in court where assets are located, but this does not extinguish jurisdiction of Seat Court: HC (See 'Legal Desk') IICA convenes 5th Inter-Ministerial Consultation on Responsible Business Conduct and ESG (See 'Corp Brief') BCCL Organizes Interaction with NRS Linkage and CIL SWMA e-Auction Consumers (See 'Corp Brief') Madnaviya & Kumaraswamy lay foundation of indoor sports complex in Karnataka (See 'Corp Brief') A&C - Juridical seat of arbitration is determinative factor for conferring exclusive supervisory jurisdiction on court: HC (See 'Legal Desk') India's progress in reducing Tuberculosis Incidence has Outpaced Global Average: Nadda (See 'Corp Brief') Rs 100 crore sanctioned for Integrated Aqua Park Project in Anantnag (See 'Corp Brief') Reddy inaugurates Multiple Projects in WCL (See 'Corp Brief') PMLA - If mortgaged properties are to be auctioned by bank or settled with borrower which may result in concealment, it would be only of those properties which was considered to be assets disproportionate to known source: SAFEMA (See 'Legal Desk') Supreme Court Clears Path For Single Insolvency Proceedings Against Linked Group Companies (See CORP EINSICHT)

Print

Glenmark's Swiss arm gets nod to market Ryaltris nasal spray in Russia

Published: Feb 22, 2021

By TIOLCORPLAWS News Service

NEW DELHI, FEB 22, 2021: GLENMARK Pharmaceuticals on Monday said its Swiss subsidiary, Glenmark Specialty, has received marketing approval from Russian health regulators for its fixed-dose combination nasal spray, Ryaltris.

Ryaltris is indicated for symptomatic treatment of seasonal and perennial allergic rhinitis, like stuffy and runny nose, nasal itching, sneezing, as well as irritated eyes, in adults and children over 12 years of age.

"Glenmark has built strong capabilities in the area of respiratory medicine and is among the leading players in this therapy area across several markets globally. Russia is one of the key markets for us and we are consistently looking to expand our product portfolio," said Csaba Kantor, Senior Vice President - Russia and CIS region, Glenmark.

In Russia, allergic rhinitis affects 10-20 per cent of the population on average, with certain regions having a higher prevalence rate of 18-38 per cent.

"Glenmark has a strong established presence in Russia for over 30 years, which will enable us to lead the commercialization of this product in the country. We look forward to being able to make this innovative product available to patients in Russia as soon as possible," Mr Kantor added.

The company estimated that Ryaltris will be available to patients in Russia by the first quarter of 2021-22.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.